Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Vitamin D and benign prostatic hyperplasia -- a review.

Espinosa G, Esposito R, Kazzazi A, Djavan B.

Can J Urol. 2013 Aug;20(4):6820-5. Review.

2.

Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia.

Gacci M, Eardley I, Giuliano F, Hatzichristou D, Kaplan SA, Maggi M, McVary KT, Mirone V, Porst H, Roehrborn CG.

Eur Urol. 2011 Oct;60(4):809-25. doi: 10.1016/j.eururo.2011.06.037. Epub 2011 Jun 29. Review.

PMID:
21726934
3.

The vitamin D receptor agonist elocalcitol inhibits IL-8-dependent benign prostatic hyperplasia stromal cell proliferation and inflammatory response by targeting the RhoA/Rho kinase and NF-kappaB pathways.

Penna G, Fibbi B, Amuchastegui S, Corsiero E, Laverny G, Silvestrini E, Chavalmane A, Morelli A, Sarchielli E, Vannelli GB, Gacci M, Colli E, Maggi M, Adorini L.

Prostate. 2009 Apr 1;69(5):480-93. doi: 10.1002/pros.20896.

PMID:
19107880
4.

A new experimental rat model of erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: the testosterone-supplemented spontaneously hypertensive rat.

Oudot A, Oger S, Behr-Roussel D, Caisey S, Bernabé J, Alexandre L, Giuliano F.

BJU Int. 2012 Nov;110(9):1352-8. doi: 10.1111/j.1464-410X.2012.11085.x. Epub 2012 Mar 27.

5.

Comprehensive patient evaluation for benign prostatic hyperplasia.

Jepsen JV, Bruskewitz RC.

Urology. 1998 Apr;51(4A Suppl):13-8. Review.

PMID:
9586591
6.

Autonomic nervous system overactivity in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia.

McVary KT, Rademaker A, Lloyd GL, Gann P.

J Urol. 2005 Oct;174(4 Pt 1):1327-433.

PMID:
16145413
7.

Shrinkage of experimental benign prostatic hyperplasia and reduction of prostatic cell volume by a gastrin-releasing peptide antagonist.

Rick FG, Abi-Chaker A, Szalontay L, Perez R, Jaszberenyi M, Jayakumar AR, Shamaladevi N, Szepeshazi K, Vidaurre I, Halmos G, Krishan A, Block NL, Schally AV.

Proc Natl Acad Sci U S A. 2013 Feb 12;110(7):2617-22. doi: 10.1073/pnas.1222355110. Epub 2013 Jan 28.

8.

Pygeum africanum for benign prostatic hyperplasia.

Wilt T, Ishani A, Mac Donald R, Rutks I, Stark G.

Cochrane Database Syst Rev. 2002;(1):CD001044. Review.

PMID:
11869585
9.

The role of combination medical therapy in benign prostatic hyperplasia.

Greco KA, McVary KT.

Int J Impot Res. 2008 Dec;20 Suppl 3:S33-43. doi: 10.1038/ijir.2008.51. Review.

PMID:
19002123
10.

Des (1-3) IGF-I-stimulated growth of human stromal BPH cells is inhibited by a vitamin D3 analogue.

Crescioli C, Villari D, Forti G, Ferruzzi P, Petrone L, Vannelli GB, Adorini L, Salerno R, Serio M, Maggi M.

Mol Cell Endocrinol. 2002 Dec 30;198(1-2):69-75.

PMID:
12573816
11.

A review of combination therapy in patients with benign prostatic hyperplasia.

McVary KT.

Clin Ther. 2007 Mar;29(3):387-98. Review.

PMID:
17577460
12.

Benign prostatic hyperplasia: clinical overview and value of diagnostic imaging.

Grossfeld GD, Coakley FV.

Radiol Clin North Am. 2000 Jan;38(1):31-47. Review.

PMID:
10664665
13.

Dutasteride improves outcomes of benign prostatic hyperplasia when evaluated for prostate cancer risk reduction: secondary analysis of the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial.

Roehrborn CG, Nickel JC, Andriole GL, Gagnier RP, Black L, Wilson TH, Rittmaster RS.

Urology. 2011 Sep;78(3):641-6. doi: 10.1016/j.urology.2011.03.063. Epub 2011 Jul 20.

PMID:
21764428
14.

[Prevalence of benign prostatic hyperplasia in Pingliang, Gansu: investigation and clinical analysis].

Han XF, Ren JL, Hu LM, Chen FR, Xu KX.

Zhonghua Nan Ke Xue. 2013 Apr;19(4):324-7. Chinese.

PMID:
23678711
15.
16.

Deficiency of vitamin D and elevated aldosterone in prostate hyperplasia.

Yalçınkaya S, Eren E, Eroglu M, Aydin O, Yilmaz N.

Adv Clin Exp Med. 2014 May-Jun;23(3):441-6.

17.

Managing the progression of lower urinary tract symptoms/benign prostatic hyperplasia: therapeutic options for the man at risk.

Emberton M, Zinner N, Michel MC, Gittelman M, Chung MK, Madersbacher S.

BJU Int. 2007 Aug;100(2):249-53. Review.

18.

Non-steroidal anti-inflammatory drug use and the risk of benign prostatic hyperplasia-related outcomes and nocturia in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.

Sutcliffe S, Grubb Iii RL, Platz EA, Ragard LR, Riley TL, Kazin SS, Hayes RB, Hsing AW, Andriole GL; Urologic Diseases in America Project.

BJU Int. 2012 Oct;110(7):1050-9. doi: 10.1111/j.1464-410X.2011.10867.x. Epub 2012 Mar 19.

19.

Selective estrogen receptor modulators regulate stromal proliferation in human benign prostatic hyperplasia by multiple beneficial mechanisms--action of two new agents.

Kumar R, Verma V, Sarswat A, Maikhuri JP, Jain A, Jain RK, Sharma VL, Dalela D, Gupta G.

Invest New Drugs. 2012 Apr;30(2):582-93. doi: 10.1007/s10637-010-9620-2. Epub 2010 Dec 23.

PMID:
21181231
20.

Ursolic acid reduces prostate size and dihydrotestosterone level in a rat model of benign prostatic hyperplasia.

Shin IS, Lee MY, Jung DY, Seo CS, Ha HK, Shin HK.

Food Chem Toxicol. 2012 Mar;50(3-4):884-8. doi: 10.1016/j.fct.2012.01.007. Epub 2012 Jan 15.

PMID:
22266360
Items per page

Supplemental Content

Write to the Help Desk